RéférencesB-G-HBrideau C., Gunter B., Pikounis W., Pajni N. et Liaw A. (2003) "Improved Statistical Methods for Hit Selection in High-Throughput Screening." 1. Biomo!. Screen., 8,634-647.
Gagarin A., Kevorkov D., Makarenkov V. et Zentilli P. (2006) «Comparison of two methods for detecting and correcting systematic error in high-throughput screening data.» In Data Science and Classification, IFCS 2006, 241-249. Heuer C., Haenel T. et Prause B. (2003) "A novel approach for quality control and correction of HTS data based on artificial intelligence." The Pharmaceutical Discovery & Development Report, PharmaVentures Ltd. Heyse.S. (2002) Comprehensive analysis of high-throughput screening da,a. In Proceedings of SNE 2002. Bellingham. WA 4626. 535-547. Hubbard R.E. (2005). 3D structure and the drug-discovery process. Mol. BioSyst 1, 391-406. K-MKaul, A. (2005): The impact of sophisticated data analysis on the drug discovery process. Business Briefing: Future Drug Discovery 2005.
Kevorkov D. et Makarenkov V. (2005a) "Statistical analysis of systematic errors in high-throughput screening." 1. Biomol. Screen., 10,557-567. Kevorkov D. et Makarenkov V. (2005b) "Quality control and data correction in highthroughput screening." Proceedings ofSFC 2005, 159-163. Keiser M.J., Setola V., Irwin J.J., Laggner C., Abbas A.I., Hufeisen S.J., Jensen N.H.,Kuiler M.B., Matos R.C., Tran T.B.et al. (2009). Predicting new molecular targets for known drugs. Nature 462, 175-182. Malo N., Hanley lA, Cerquozzi S., Pelletier J. et Nadon R. (2006) "Statistical practice in high-throughput screening data analysis." Nature Biotechnol., 24, 167-175. Makarenkov V., Kevorkov D., Zentilli P., Gagarin A, Malo N. et Nadon R. (2006) "HTS-Corrector: software for the statistical analysis and correction of experimental high-throughput screening data." Bioinformatics, 22,1408-1409. Makarenkov V., Zentilli P., Kevorkov D., Gagarin A, Malo N. et Nadon R. (2007) "An efficient method for the detection and elimination of systematic errors in high-throughput screening." Bioinformatics, 23, 1648-1657. Maréchal E ., Roy S., Lafanechère L., Une introduction à l'usage des biologistes, Chimistes et informaticiens. EDP Sciences, 2007. |
O-T-V-ZOprea T.I., Matter H. (2004). Integrating virtual screening in lead discovery. Curr. Opin. Chem. Biol. 8, 349-358.
Tuccinardi T. (2009). Docking-based virtual screening: recent developments. Comb. Chem. High Throughput Screen. 12, 303-314. Tukey,J.W. (1977) Exp/oralory DOlO Ana(vsis. Cambridge. MA. Addison-Wesley. Vistoli G., Pedretti A., Testa B. (2008). Assessing drug-likeness – what are we missing?. Drug Discov. Today 13, 285-294. Zhang J.H., Chung T.D.Y et Oldenburg,K.R. (2000) "Confirmation ofprimary active substances from high throughput screening of chemical and biological populations: a statistical approach and practical considerations." J. Comb. Chem., 2, 258-265. |